Surgery Partners Gestione
Criteri Gestione verificati 4/4
Surgery Partners Il CEO è J. Evans, nominato in Jan2020, e ha un mandato di 6.58 anni. la retribuzione annua totale è $ 6.08M, composta da 17.3% di stipendio e 82.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.71% delle azioni della società, per un valore di $ 14.40M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.5 anni e 7.6 anni.
Informazioni chiave
J. Evans
Amministratore delegato
US$6.1m
Compenso totale
| Percentuale dello stipendio del CEO | 17.26% |
| Mandato del CEO | 6.6yrs |
| Proprietà del CEO | 0.7% |
| Durata media del management | 4.5yrs |
| Durata media del Consiglio di amministrazione | 7.6yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento narrativa • Jun 30
SGRY: Q1 Execution And 2026 Outlook Will Support Margin Recovery
Analysts have revised their fair value estimate for Surgery Partners from $25.00 to about $23.49, citing updated assessments of discount rates, revenue growth, profit margins, and future P/E assumptions based on recent research. Analyst Commentary Recent Street research around Surgery Partners highlights a mix of adjustments to price targets, with some bullish analysts focusing on the company’s capacity to execute on its plans while reassessing risk and return assumptions.Articolo di analisi • Jun 19
Surgery Partners (SGRY) Stock Could Be 19% Undervalued As Growth And Debt Concerns Build
Recent commentary on Surgery Partners (SGRY) has focused on slowing sales volume growth, softer revenue growth expectations, and ongoing high debt levels. This combination appears to be affecting sentiment toward the stock. See our latest analysis for Surgery Partners. At a share price of $14.55, Surgery Partners has seen a 30 day share price return of 7.86% and a 90 day share price return of 23.31%. However, the 1 year total shareholder return is down 24.61%, pointing to some recent momentum...
Aggiornamento narrativa • Jun 15
SGRY: Reset Expectations And Steady Guidance Will Shape Future Multiple Potential
Analysts cut the fair value estimate for Surgery Partners stock by $4 to $14, reflecting updated assumptions around revenue growth, profit margins, the discount rate, and a lower future P/E multiple, despite recent mixed price target moves at Jefferies. Analyst Commentary Recent research shows mixed views on Surgery Partners, with some analysts adjusting price targets in both directions over a short period.
Aggiornamento narrativa • Jun 01
SGRY: Margin Repair And Payer Mix Reset Will Support 2026 EBITDA Recovery
The analyst-derived fair value estimate for Surgery Partners has shifted from about $18.80 to roughly $17.95, as analysts factor in recent price target cuts tied to Q4 margin pressures, a softer 2026 EBITDA outlook, and concerns around payer mix, anesthesia costs, and a slower M&A contribution. Analyst Commentary Recent Street research around Surgery Partners has been active, with multiple firms revisiting their models after Q4 results and updated 2026 guidance.Aggiornamento narrativa • May 02
SGRY: Margin Pressures Will Ease As 2026 M&A Upside Reemerges
Narrative Update on Surgery Partners Analysts have trimmed the average price target for Surgery Partners by a few dollars into the mid to high teens, citing Q4 EBITDA and margin shortfalls, a weaker payer mix, anesthesia related cost pressures, softer 2026 guidance, and reduced expectations for M&A contribution. Analyst Commentary Price targets across the Street have been revised lower into a tighter band, generally in the mid to low US$20s and mid to high teens, following the Q4 miss and 2026 EBITDA guidance that came in below prior expectations.Aggiornamento narrativa • Apr 18
SGRY: Margin Pressures Will Ease As M&A Optionality Reshapes 2026 Outlook
Analysts have reduced the average price target for Surgery Partners by roughly $8 to $10 per share to a range of about $14 to $24, citing Q4 EBITDA shortfalls, margin pressures from payer and insurance mix shifts, anesthesia related costs, and softer 2026 guidance that excludes potential M&A. Analyst Commentary Recent research shows that while price targets have moved lower across the Street, several bullish analysts still see upside potential for Surgery Partners relative to current trading levels.Aggiornamento narrativa • Apr 04
SGRY: Margin Repair And Payer Mix Management Will Support A Constructive 2026 Reset
The analyst price target for Surgery Partners has been reduced from about $25.45 to about $18.80. Analysts cite weaker Q4 EBITDA, margin pressure from a tougher payer and insurance mix, anesthesia-related cost pressures, and more cautious 2026 guidance as key drivers of their updated views.Aggiornamento narrativa • Mar 21
SGRY: Margin Reset And M&A Optionality Will Counter Anesthesia And Payer Mix Pressures
Narrative Update on Surgery Partners The analyst price target for Surgery Partners has moved lower by several dollars into a $14 to $24 range, as analysts factor in recent Q4 EBITDA shortfalls, weaker margins, anesthesia and payer mix headwinds, and management's 2026 guidance that sits below prior consensus and assumes limited M&A. Analyst Commentary Recent Street commentary on Surgery Partners centers on Q4 earnings that came in below expectations, margin pressure tied to anesthesia costs, and a less favorable payer mix.Aggiornamento narrativa • Mar 06
SGRY: Margin Reset And M&A Optionality Are Expected To Ease Payer Mix Pressures
The analyst fair value estimate for Surgery Partners has been reduced from $33.00 to $25.00 as analysts factor in lower Q4 EBITDA, margin pressure related to payer mix and anesthesia costs, and softer 2026 guidance that assumes fewer deals than previously modeled. Analyst Commentary Street research has broadly reset expectations on Surgery Partners, with several firms lowering their price targets after Q4 results and the updated 2026 outlook.Aggiornamento narrativa • Feb 20
SGRY: New Baylor Partnership Will Set Up Future Multiple Rebound Potential
Analysts have kept their $18.00 price target for Surgery Partners unchanged, citing consistent assumptions regarding revenue growth, profit margins, and future P/E as support for this view. What's in the News Surgery Partners agreed to a new partnership with Baylor Scott & White Health to jointly own The Physicians Centre Hospital, a 16 bed facility in Bryan, Texas, alongside physicians (Key Developments).Aggiornamento narrativa • Feb 06
SGRY: Payer Mix Pressures Will Set Up Future Multiple Rebound Potential
Analysts have reduced their price target on Surgery Partners to US$18 from US$24, citing weaker earnings visibility from payer mix and volume pressures, a higher discount rate, more conservative revenue growth assumptions, and an adjustment to a lower future P/E multiple. Analyst Commentary Recent research updates on Surgery Partners point to a reset in expectations, with several firms cutting price targets across the board.Aggiornamento narrativa • Jan 23
SGRY: Asset Divestitures And Deleveraging Are Expected To Reset Payer Mix Pressures
Narrative Update Analysts have reduced their price targets on Surgery Partners to a range of roughly US$18 to US$31, citing lower earnings visibility tied to payer mix and volume pressures, slower M&A activity, and updated guidance that still assumes a favorable backdrop for asset divestitures and ambulatory surgery center demand. Analyst Commentary Across recent research updates, analysts have generally reduced price targets for Surgery Partners into the US$18 to US$31 range while still highlighting several areas that they see as supportive for the equity story.Aggiornamento narrativa • Jan 09
SGRY: Upcoming Divestitures And Deleveraging Will Support A Constructive 2025 Reset
Analysts have trimmed their price targets on Surgery Partners, resulting in a modest change in estimated fair value from about $25.73 to $25.45, as they factor in payer mix pressure, softer recent performance, slower M&A activity, and updated expectations for volumes and earnings visibility. Analyst Commentary Recent research paints a mixed picture for Surgery Partners, with price targets moving lower but opinions split on how temporary the current pressures might be.Aggiornamento narrativa • Dec 25
SGRY: Upcoming Asset Divestitures Are Expected To Drive Material Balance Sheet Deleveraging
Analysts have trimmed their fair value estimate for Surgery Partners to $33 from $36. This reflects lower price targets across the Street as they factor in softer volume trends, payer mix headwinds, reduced earnings visibility and a slower M&A cadence, partially offset by confidence in long term ASC tailwinds and de-leveraging from asset divestitures.Aggiornamento narrativa • Dec 11
SGRY: Upcoming Divestitures And Deleveraging Will Drive A Constructive Reset In 2025
Surgery Partners price target has been revised lower, with analysts trimming expectations by mid single digit dollars per share to reflect weaker than expected recent performance, payer mix and volume pressures, slower M&A activity, and reduced near term earnings visibility, even as they highlight supportive long term fundamentals and a still constructive outlook on asset divestitures and deleveraging. Analyst Commentary Analysts are broadly revising models to reflect weaker near term trends, yet most still frame the stock as a valuation reset rather than a change in the long term thesis.Aggiornamento narrativa • Nov 27
SGRY: Upcoming Divestitures And Deleveraging Will Drive Recovery In 2025
Analysts have lowered their price target for Surgery Partners from approximately $27.91 to $25.73. They cite recent earnings misses, payer mix headwinds, and delayed acquisitions as primary factors for the revision.Aggiornamento narrativa • Nov 12
SGRY: Asset Divestitures And Acquisition Pipeline Will Drive Recovery Ahead
The analyst price target for Surgery Partners has decreased from $31 to approximately $27.91. Analysts cite lowered guidance due to slowing volume and payer mix trends, a delay in acquisitions, and a more cautious outlook for near-term growth.Seeking Alpha • Sep 08
Surgery Partners: Deleveraging Needs To Be The Priority
Summary Surgery Partners now trades at fair value after multiple compression, with returns on capital still lagging and leverage elevated, justifying my Hold rating. Q2 results were decent, but cash flow conversion and ambitious H2 margin targets highlight execution risks and limited room for error. Business economics show SGRY is capital intensive, with ROIC below the cost of capital, so growth currently destroys value unless returns improve. To upgrade my stance, I need to see sustained high-teen margins, clear deleveraging, and a shift to higher organic growth over acquisitions. Read the full article on Seeking AlphaNuova narrativa • May 26
Ambulatory Surgery Trends And Aging Will Expand Market Reach
Growth is driven by rising surgical case volumes in lower-cost centers and expanded specialties, supported by demographic trends and strategic network expansion.Seeking Alpha • Jan 30
Surgery Partners: A Buyout Could Be Justifiable Around This Level
Summary Surgery Partners received a non-binding offer from Bain Capital to acquire the rest of the company for $25.75 per share, valuing it at $3.25 billion. In the past, the stock had been pricey, but this is no longer the case based on current pricing. In recent years, financial performance has been solid and improving, particularly when it comes to cash flows. The market is cautiously optimistic about the offer, suggesting potential for a higher bid, but significant upside is unlikely. Read the full article on Seeking AlphaArticolo di analisi • Dec 08
Market Cool On Surgery Partners, Inc.'s (NASDAQ:SGRY) Revenues Pushing Shares 28% Lower
The Surgery Partners, Inc. ( NASDAQ:SGRY ) share price has fared very poorly over the last month, falling by a...Articolo di analisi • Nov 11
Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Oct 24
Market Cool On Surgery Partners, Inc.'s (NASDAQ:SGRY) Revenues
It's not a stretch to say that Surgery Partners, Inc.'s ( NASDAQ:SGRY ) price-to-sales (or "P/S") ratio of 1.4x right...Articolo di analisi • Oct 05
Surgery Partners (NASDAQ:SGRY) Has Some Way To Go To Become A Multi-Bagger
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Typically, we'll want to notice a...Articolo di analisi • Jul 25
Surgery Partners, Inc. (NASDAQ:SGRY) Soars 25% But It's A Story Of Risk Vs Reward
Surgery Partners, Inc. ( NASDAQ:SGRY ) shareholders would be excited to see that the share price has had a great month...Articolo di analisi • Jul 13
Here's Why Surgery Partners (NASDAQ:SGRY) Has A Meaningful Debt Burden
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Articolo di analisi • Jun 21
Slowing Rates Of Return At Surgery Partners (NASDAQ:SGRY) Leave Little Room For Excitement
To find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...Articolo di analisi • May 31
We Think Shareholders Are Less Likely To Approve A Pay Rise For Surgery Partners, Inc.'s (NASDAQ:SGRY) CEO For Now
Key Insights Surgery Partners will host its Annual General Meeting on 6th of June CEO J. Evans' total compensation...Articolo di analisi • Apr 24
Surgery Partners, Inc.'s (NASDAQ:SGRY) Share Price Matching Investor Opinion
There wouldn't be many who think Surgery Partners, Inc.'s ( NASDAQ:SGRY ) price-to-sales (or "P/S") ratio of 1.2x is...Articolo di analisi • Mar 18
Surgery Partners' (NASDAQ:SGRY) Returns Have Hit A Wall
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Articolo di analisi • Feb 27
Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Dec 19
The Price Is Right For Surgery Partners, Inc. (NASDAQ:SGRY)
There wouldn't be many who think Surgery Partners, Inc.'s ( NASDAQ:SGRY ) price-to-sales (or "P/S") ratio of 1.5x is...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$76m |
| Dec 31 2025 | US$6m | US$1m | -US$78m |
| Sep 30 2025 | n/a | n/a | -US$171m |
| Jun 30 2025 | n/a | n/a | -US$180m |
| Mar 31 2025 | n/a | n/a | -US$193m |
| Dec 31 2024 | US$6m | US$1m | -US$168m |
| Sep 30 2024 | n/a | n/a | -US$61m |
| Jun 30 2024 | n/a | n/a | -US$34m |
| Mar 31 2024 | n/a | n/a | US$600k |
| Dec 31 2023 | US$6m | US$1m | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$34m |
| Jun 30 2023 | n/a | n/a | -US$54m |
| Mar 31 2023 | n/a | n/a | -US$92m |
| Dec 31 2022 | US$6m | US$1m | -US$55m |
| Sep 30 2022 | n/a | n/a | -US$31m |
| Jun 30 2022 | n/a | n/a | -US$29m |
| Mar 31 2022 | n/a | n/a | -US$38m |
| Dec 31 2021 | US$4m | US$1m | -US$81m |
| Sep 30 2021 | n/a | n/a | -US$86m |
| Jun 30 2021 | n/a | n/a | -US$135m |
| Mar 31 2021 | n/a | n/a | -US$150m |
| Dec 31 2020 | US$4m | US$916k | -US$156m |
| Sep 30 2020 | n/a | n/a | -US$179m |
| Jun 30 2020 | n/a | n/a | -US$132m |
| Mar 31 2020 | n/a | n/a | -US$119m |
| Dec 31 2019 | US$5m | US$435k | -US$110m |
Compensazione vs Mercato: La retribuzione totale di J. ($USD 6.08M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 5.10M ).
Compensazione vs guadagni: La retribuzione di J. è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
J. Evans (49 yo)
6.6yrs
Mandato
US$6,083,862
Compensazione
Mr. J. Eric Evans has been the Chief Executive Officer and Director of Surgery Partners, Inc. since January 13, 2020 and served as its Executive Vice President and Chief Operating Officer since April 1, 20...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 6.6yrs | US$6.08m | 0.71% $ 14.4m | |
| Executive VP & CFO | 4.5yrs | US$2.68m | 0.17% $ 3.5m | |
| Executive VP and Chief Administrative & Development Officer | 6.5yrs | US$2.18m | 0.25% $ 5.1m | |
| Executive VP & Chief Strategy Officer | 4.6yrs | US$1.12m | 0.073% $ 1.5m | |
| Division President South | no data | US$1.27m | 0.081% $ 1.6m | |
| Executive VP & COO | less than a year | Nessun dato | 0.093% $ 1.9m | |
| Senior VP & Chief Information Officer | 1.3yrs | Nessun dato | Nessun dato | |
| Senior VP & Chief Compliance Officer | 7.8yrs | Nessun dato | Nessun dato | |
| General Counsel & Senior VP | 2.4yrs | Nessun dato | Nessun dato | |
| Executive VP & Chief Human Resources Officer | 3.5yrs | Nessun dato | 0.059% $ 1.2m | |
| Senior Vice President of Managed Care | 6.8yrs | Nessun dato | Nessun dato | |
| Senior VP & Enterprise Chief Clinical Officer | 2.7yrs | Nessun dato | Nessun dato |
4.5yrs
Durata media
46yo
Età media
Gestione esperta: Il team dirigenziale di SGRY è considerato esperto (durata media dell'incarico 4.5 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 6.6yrs | US$6.08m | 0.71% $ 14.4m | |
| Independent Director | 8.8yrs | US$260.00k | 0.053% $ 1.1m | |
| Independent Chairman of the Board | 5.3yrs | US$345.00k | 0.041% $ 827.8k | |
| Independent Director | less than a year | Nessun dato | 0.0090% $ 182.7k | |
| Independent Director | 10.7yrs | US$465.00k | 0.067% $ 1.4m | |
| Independent Director | 9.9yrs | US$430.00k | 0.044% $ 889.7k | |
| Independent Director | 7.3yrs | US$410.00k | 0.035% $ 718.7k | |
| Independent Director | 9yrs | Nessun dato | Nessun dato | |
| Independent Director | 1.6yrs | US$410.00k | 0.014% $ 290.0k | |
| Independent Director | 8yrs | Nessun dato | Nessun dato |
7.6yrs
Durata media
60.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di SGRY sono considerati esperti (durata media dell'incarico 7.6 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/05 10:49 |
| Prezzo dell'azione a fine giornata | 2026/08/05 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Surgery Partners, Inc. è coperta da 21 analisti. 11 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Steven Valiquette | Barclays |
| Sarah James | Barclays |
| Andrew Mok | Barclays |